- Home
- BLNK vs PLRX Comparison
BLNK vs PLRX Comparison
Compare BLNK & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- PLRX
- Stock Information
- Founded
- BLNK 2009
- PLRX 2015
- Country
- BLNK United States
- PLRX United States
- Employees
- BLNK N/A
- PLRX N/A
- Industry
- BLNK Industrial Specialties
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- PLRX Health Care
- Exchange
- BLNK Nasdaq
- PLRX Nasdaq
- Market Cap
- BLNK 73.4M
- PLRX 84.7M
- IPO Year
- BLNK N/A
- PLRX 2020
- Fundamental
- Price
- BLNK $0.70
- PLRX $1.42
- Analyst Decision
- BLNK Buy
- PLRX Hold
- Analyst Count
- BLNK 8
- PLRX 10
- Target Price
- BLNK $2.61
- PLRX $9.79
- AVG Volume (30 Days)
- BLNK 2.4M
- PLRX 1.0M
- Earning Date
- BLNK 05-12-2025
- PLRX 05-08-2025
- Dividend Yield
- BLNK N/A
- PLRX N/A
- EPS Growth
- BLNK N/A
- PLRX N/A
- EPS
- BLNK N/A
- PLRX N/A
- Revenue
- BLNK $109,383,000.00
- PLRX N/A
- Revenue This Year
- BLNK N/A
- PLRX N/A
- Revenue Next Year
- BLNK $28.49
- PLRX N/A
- P/E Ratio
- BLNK N/A
- PLRX N/A
- Revenue Growth
- BLNK N/A
- PLRX N/A
- 52 Week Low
- BLNK $0.63
- PLRX $1.10
- 52 Week High
- BLNK $3.75
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- BLNK 41.86
- PLRX 46.88
- Support Level
- BLNK $0.67
- PLRX $1.22
- Resistance Level
- BLNK $0.78
- PLRX $1.41
- Average True Range (ATR)
- BLNK 0.04
- PLRX 0.09
- MACD
- BLNK -0.00
- PLRX 0.02
- Stochastic Oscillator
- BLNK 24.56
- PLRX 65.45
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.